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Summary 
Genome-wide-association-studies have identified risk loci associated with the 
development of Inflammatory Bowel Disease while epidemiological studies have 
emphasized that pathogenesis likely involves host interactions with environmental 
elements whose source and structure need to be defined. Here, we identify a class of 
compounds, derived from dietary, microbial and industrial sources that are characterized 
by the presence of a 5-membered-oxazole-ring and induce CD1d-dependent intestinal 
inflammation. We observe minimal oxazole structures modulate natural killer T cell 
dependent inflammation by regulating lipid antigen presentation by CD1d on intestinal 
epithelial cells (IEC). CD1d-restricted production of interleukin 10 by IECs is limited 
through activity of the aryl hydrocarbon receptor (AhR) pathway in response to oxazole 
induction of tryptophan-metabolites such that depletion of the AhR in the intestinal 
epithelium abrogates oxazole-induced inflammation. In summary, we identify 
environmental derived oxazoles as triggers of CD1d-dependent intestinal inflammatory 
response that occur via activation of the AhR in the intestinal epithelium. 
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Introduction 
Inflammatory bowel disease (IBD) is a complex disorder that evolves from the 
interactions between poorly understood environmental factors and a host’s genetic 
framework that together define susceptibility to and severity of disease. Pathology is 
influenced by specific host elements that include the autochthonous commensal 
microbiota, which is acquired at birth, the intestinal epithelial cell barrier and subjacent 
immune cells within the intestinal mucosa (Kaser et al. 2010). One of the great 
challenges of understanding IBD pathogenesis stems from efforts to elucidate the 
molecular details surrounding the environmental basis for these disorders. This is 
increasingly important since epidemiologic studies have revealed a rapid global 
expansion of these diseases that includes geographic regions, which have heretofore 
been unaffected (Molodecky and Kaplan 2010). 
A potential opportunity to investigate this question has emerged from recent 
studies on the role of CD1d and natural killer T cells (NKT) in mucosal biology. CD1d is 
a major histocompatibility complex (MHC) class I-related molecule that presents cell 
associated and microbial lipid antigens to NKT cells (Brennan et al. 2013). In the 
intestines, CD1d is expressed by intestinal epithelial cells (IEC), and hematopoietic cells 
and present endogenous (self) or exogenous lipid antigens to NKT cells expressing an 
invariant T cell receptor (TCR)  chain (iNKT cells) or a semi-diverse (d) set of TCR- 
chains (dNKT), which are present in human and mouse intestines (RossJohn et al. 2012, 
Van de waal et al 2003, Colgan et al. 1999). 
Experimental models using chemical induction of colitis using a classic hapten, 
oxazolone (Wirtz et al. 2007) implicate a role for NKT cells in the pathogenesis of IBD 
and has been corroborated in some patient studies (Fuss et al. 2004). Boirevant and 
colleagues first demonstrated that administration of oxazolone directly to the colon in 
ethanol of SJL/J mice, or in later studies indirectly after skin painting and sensitization 
suggesting a model of haptenization, resulted in a severe acute, superficial inflammation 
due to the production of interleukin (IL)-4 and IL-13 that was counter-balanced by tumor 
growth factor- which delimited the inflammation to the distal colon (Boirevant et al. 
1998). This restriction to type 2 cytokines was eventually recognized to be genetically 
based as similar studies in C57Bl/6 mice revealed inflammation in association with 
oxazolone that was due to type 1 cytokines (namely interferon-) derived from 
hematopoietic cells (Olszak et al. 2014). In later groundbreaking studies by Heller and 
colleagues, it was recognized that oxazolone-induced colitis was dependent upon CD1d 
and iNKT cells as an inflammatory response to oxazolone was abrogated by the deletion 
of Cd1d or J18, encoding the invariant TCR- chain (Heller et al. 2002), primarily 
derived from the activity of professional APC in the lamina propria using bone marrow 
chimeras (Olszak et al. 2014). In contrast, CD1d-expressing IECs were shown to secrete 
anti-inflammatory IL-10 in response to iNKT cells in a CD1d-dependent manner, which 
serves to restrain oxazolone-induced inflammation derived from the hematopoietic 
system (Colgan et al. 1999, Olzsak et al. 2014). Thus, when CD1d-restricted pathways 
in the IEC are specifically eliminated by conditional genetic deletion of Cd1d, microsomal 
triglyceride transfer protein (Mttp), an endoplasmic reticulum resident protein which 
serves to regulate CD1d lipidation and its ability to function, or Il10, oxazolone-induced 
colitis is unrestrained and severe (Dougan et al. 2005, 2007, Sagiv et al. 2007, Olszak et 
al. 2014). Human studies have further identified a potential role for dNKT cells in IBD by 
showing elevated IL-13 production by lamina propria mononuclear cells in response to 
sulfatide, a CD1d-restricted self-antigen which can activate iNKT and dNKT cells (Fuss 
et al. 2004, Fuss et al. 2014). Further, T cell receptor (TCR) transgenic mice expressing 
a non-invariant CD1d-restricted TCR develop colitis (Wang et al. 2017) though their 
exact role during the pathogenesis of IBD remains unknown (Grose et al. 2007, van der 
Vliet et al. 2001). 
 Importantly, host inflammatory responses to oxazolone occur even in animals 
raised under germ free (GF) conditions, indicating that NKT cell mediated response to 
self (rather than microbial) lipid antigens presented by CD1d on professional and/or non-
professional antigen presenting cells (APC) is sufficient for pathogenesis (Olszak et al. 
2012). Instead, commensal bacteria themselves can modulate the magnitude of NKT 
cell responses either by directly altering the CD1d-restricted lipid antigen reservoir (An et 
al. 2014, Wieland Brown et al. 2013) or indirectly by regulating the quantity of iNKT cells 
in the colon (Olszak et al. 2012). Conversely, CD1d itself plays a critical role in 
regulating the composition and extent of colonization by both commensal and 
pathogenic microbial species potentially through disruption of the anti-microbial activity 
of Paneth cells (Nieuwenhuis et al. 2005, 2009). 
The similarities between these biological observations in mouse models and 
current hypotheses for IBD pathogenesis lead us to hypothesize that oxazolone may be 
an example of a much larger collection of environmental chemical moieties capable of 
triggering CD1d-restricted iNKT cell responses. Consistent with this, we have identified 
environmental mimetics of oxazolone that are derived from dietary, industrial or microbial 
sources which are characterized by the presence of a 5-membered oxazole ring and 
capable of driving CD1d-dependent inflammation through activation of the aryl 
hydrocarbon receptor pathway within IECs of the colon. As efforts to define and evaluate 
natural and synthetic chemicals involved in homeostasis or disease have generally been 
elusive, these results have broad implications for understanding the environmental basis 
of mucosal diseases such as IBD. 
Results 
Defining a structural moiety that modulates epithelial derived CD1d dependent 
inflammatory responses. 
4-ethoxymethylene-2-phenyl-2-oxazol-5-one, (referred to as oxazolone, Fig. 1A) has 
been widely utilized in models of contact hypersensitivity and when applied to the 
mucosa has been proposed to cause colitis through its properties as a hapten 
(Gorbachev and Fairchild 2001).  However to date there is limited evidence for hapten-
specific antibody production or responses following topical oxazolone sensitization or 
hapten modified autologous proteins or luminal antigens identified at mucosal sites 
(Singleton et al. 2016, Wirtz et al. 2007). Interestingly, upon analysis of previously 
published microarray studies derived from epithelial enriched colon fractions following 
intra-rectal oxazolone challenge (Olszak et al. 2014), we observed decreased 
expression of microsomal triglyceride transfer protein (Mttp, MTP) and increased 
expression for elements associated with aryl hydrocarbon receptor (AhR) signaling, 
including P450 enzymes (cyp1a1) and indoleamine 2,3-dioxygenase (Ido1). We 
therefore asked whether oxazolone could affect the expression of these transcripts in the 
intestinal epithelium in a cell intrinsic manner by directly stimulating an immortalized 
intestinal epithelial cell line (IEC) derived from mouse small intestine, MODE-K, with 
oxazolone. We observed down-regulation of Mttp and induction of metabolic genes 
cyp1a1 and Ido1 (Fig. 1B, S1A).  
MTP is a critical regulator of mucosal homeostasis that promotes epithelial 
barrier activity by controlling CD1d-restricted IL-10 production by epithelial cells (Colgan 
et al. 1999, Olszak et al. 2014). Thus IEC specific deletion of Mttp results in decreased 
CD1d-stimulated IL-10 production by the IEC leading to the exaggerated inflammatory 
activity of hematopoietic cells in response to oxazolone challenge resulting in increased 
colitis (Olszak et al. 2014). We modeled interactions between NKT cells and IECs using 
MODE-K cells and CD1d-restricted T cell hybridomas in a previously established CD1d-
dependent co-culture system (van de Wal et al. 2003). These studies have shown that 
loading of CD1d with alpha-galactosyl ceramide (-GC), a cognate lipid antigen, in this 
co-culture system, leads to MTP-dependent, CD1d-restricted IL-10 production that is 
primarily derived from the IEC (Brozovic et al. 2004, Colgan et al. 1999, Olzsak et al. 
2014). Here, we found that MODE-K cells pre-conditioned with oxazolone exhibited 
attenuated IL-10 production in response to -GC when placed in co-culture with an iNKT 
cell hybridoma (24.7), which specifically reacts to -GC presented on CD1d (Fig. 1C). 
Interestingly, epithelial derived IL-10 was also suppressed when IECs stimulated with 
oxazolone were co-cultured with an autoreactive iNKT cell hybridoma (24.8) or an 
autoreactive non-invariant dNKT cell hybridoma (14S.6) in the absence of exogenously 
administered -GC (Fig. S1B, S1C). These effects were specific to the IEC as co-culture 
of bone marrow-derived dendritic cells with the 24.7 iNKT cell hybridoma and -GC lead 
to production of IFN-(Fig. S1D) but not IL-10 (data not shown) which was not affected 
by oxazolone or any of the oxazolone-related compounds described below. 
In light of the decreased MTP expression observed in oxazolone treated IECs 
(Fig. 1B) and given that MTP loss alters the ability of CD1d to acquire exogenous 
antigens, such as -GC, and CD1d elicited IL-10 responses by epithelial cells (Dougan 
et al. 2005, Dougan et al. 2007, Sagiv et al. 2007, Brozovic et al. 2004, Olszak et al. 
2014), we investigated CD1d expression and lipid loading on oxazolone conditioned 
IECs. IECs stimulated with oxazolone did not display altered CD1d protein expression or 
distribution between intracellular and cell surface pools (Fig. S2A, S2B), but instead 
exhibited decreased loading of -GC on CD1d at the cell surface (Fig. 1D, 1E). These 
results were consistent with the decreased CD1d-restricted IL-10 protein production we 
observed in MODE-K:iNKT cell co-cultures (Fig.1C, S1B, S1C), and suggest that 
oxazolone induced alterations in MTP expression were associated with decreased CD1d 
function affecting IL-10 production in response to iNKT cells.  
Oxazolone is administered in experimental models of colitis and contact 
sensitivity but is also widely used in industry and pharmaceuticals as a pharmacophore 
for the generation of synthetic compounds suggesting it may act as a potential 
environmental trigger of inflammation in sensitive hosts (Turchi 2008). We therefore 
sought to identify a library of structural mimetics of oxazolone and test whether these 
molecules behaved in a similar manner. We performed a two part in silico screen against 
three chemical databases of naturally occurring compounds (Human Metabolome 
Database, Super Natural II database, Dictionary of Natural Products) (Banerjee et al. 
2015, Wishart et al. 2007) thereby limiting our search to compounds within a defined 
human envirome. Natural compounds were queried in the standard SMILES format and 
Tanimoto similarities between oxazolone and test compounds were computed with the 
ChemMine Similarity Workbench, which calculated maximum common substructure 
(MCS) similarities with the Tanimoto coefficient. Further, Euclidean distance scores were 
calculated using a non-continuous atom matching structural similarity function (NAMS) 
(Cao et al. 2008, Teixeira et al. 2013).  An initial screen identified 33 compounds with 
MCS >0.5 and Euclidean distance scores cutoff of 0.9 (Table S1). Oxazolone consists of 
four major functional moieties: a 5-membered oxazole ring, a 2’ phenylgroup, a 4’ 
ethoxymethylene substituent, and the 5’-carbonyl lactone.  Our computational screen 
revealed the oxazole ring to be a distinctive and shared chemical sub-structure between 
the 33 compounds identified, all of which derived from dietary, microbial and/or industrial 
sources. We then employed a second screen using the same parameters but instead 
substituting a minimal oxazole ring as our template structure. The analysis led to the 
identification of 63 naturally occurring oxazole-containing (OxC) compounds (including 
the 33 described above). Of particular interest, we noticed that many of these 
compounds derived from two major sources: diet and microbes. This led us to ask 
whether oxazolone is a molecular prototype for a broader class of environmental stimuli 
that feature an oxazole sub-structure capable of modulating epithelial CD1d-restricted 
responses in a cell intrinsic manner. 
To test this, we devised a systematic in vitro system to assess transcriptional and 
CD1d-restricted responses in IECs in response to stimulation with dietary OxC 
structures, including 2,4,5-trimethyl-2,5-dihydro-1,3-oxazole (referred to as TMO, Fig. 
1A) found in coffee, peanuts, and meats, which lacks the 2-phenyl ring, 5-ketone, and 4-
ethoxymethylene present in oxazolone (Maga 1978). Like oxazolone, TMO suppressed 
Mttp and induced cyp1a1 and Ido1 transcripts in IECs (Fig. 1B, S1A). In contrast two 
structurally related non-OxC heterocyclic aromatic compounds 1,2,4-trimethyl 
cyclopentane (MCS=0.5, referred to as TMC) and 2-methyl-1-pyrroline (MCS=0.83, 
referred to as 1-MP), that substitute carbons at the 1’-oxygen and/or 3’-nitrogen, did not 
elicit any transcriptional changes in the target genes assessed (Fig. 1B). Moreover, IECs 
conditioned with oxazolone or TMO but not TMC or 1-MP limited CD1d-restricted IL-10 
production in co-cultures with an iNKT hybridoma (24.7) and consistent with decreased 
loading of -GC on CD1d at the cell surface (Fig. 1C, 1D, 1E). Overall, 5 of 7 
commercially available naturally occurring dietary OxC as well as vinclozolin (Fig. 1A, 
Table S1), an OxC fungicide used in agriculture, phenocopied the transcriptional and 
CD1d-restricted epithelial responses observed after oxazolone stimulation.  
A minimal oxazole structure induces colonic inflammation in a CD1d dependent 
manner. 
We next asked if a dietary sourced minimal oxazole structure was sufficient to induce 
intestinal inflammation in vivo. Indeed intra-rectal administration of TMO was observed 
to lead to increased weight loss and pathology characterized by superficial inflammation 
of the gut wall, neutrophil accumulation and ulceration of the epithelial layer of the colon 
that was similar to the inflammation associated with oxazolone (Fig. 1F, 1G, S3A). 
Response to TMO but not 1,2,4-trimethylcyclopentane (TMC) or vehicle was 
characterized by production of Th2 and Th1 cytokines including IL-13 and IFN- from 
colon explants (Fig. 1H). Importantly, intestinal inflammation after TMO challenge was 
dependent on the presence of iNKT cells, as CD1d-deficient animals displayed no 
evidence of clinical symptoms or pathology (Fig. 1F, 1G) as previously shown for 
oxazolone (Heller et al. 2002). In addition, host in vivo IEC responses to TMO but not 
TMC or vehicle recapitulated the transcriptional changes observed in microarray and in 
vitro analyses including downregulation of Mttp and induction of cyp1a1 (Fig. S3B, S3C). 
Importantly, these studies were performed by direct administration of TMO to the colonic 
epithelium by rectal challenge without preceding skin sensitization further suggesting 
that the OxC-induced effects observed were direct and did not require prior immune 
activation as would be expected from a hapten-induced model.  To confirm this, we 
compared the ability of oxazolone skin pre-sensitization to affect the responses to rectal 
challenge with TMO and vice-versa (Fig. S3D). These studies showed that pre-
sensitization with oxazolone or TMO did not affect rectal responses to TMO or 
oxazolone, respectively; corroborating evidence that oxazolone or TMO were having 
direct effects on the colonic mucosa.   
A microbial derived oxazole structure modulates epithelial responses and leads to 
intestinal inflammation. 
Our in silico analysis also identified a class of bacterial derived toxins featuring oxazole 
moieties with a high degree of similarity to a minimal oxazole template. These are 
termed thiazole/oxazole modified microcins (TOMMs), a family of anti-microbial peptides 
featuring the presence of thiazol(in)e and oxazol(in)e heterocycles derived from 
cysteine, serine, and threonine residues on a ribosomally produced precursor peptide 
that confer a range of anti-microbial activities including DNA gyrase inhibitors, translation 
inhibitors and hemolytic toxins (Table S1) (Melby et al. 2011, Collin et al. 2013, Lee et al. 
2008). Though chemically and functionally diverse, as a rule TOMM biosynthetic gene 
clusters encode a leader peptide, enzymatic machinery including a cyclodehydratase 
and cyclodehydrogenase, that mediate post-translational installation of oxazole/thiazole 
moieties required for biological activity, and in some cases an immunity gene that 
protects the host strain from the anti-microbial activities of the TOMM itself (Melby et al. 
2011).  Importantly, many TOMM biosynthetic gene clusters (BGC) have been described 
in a variety of human commensal communities as a means of providing host strains with 
ecological fitness advantages (Lee et al. 2008).  Within the commensal populations, 
these BGC encoded small molecule bacterial signaling factors collectively have an 
enormous potential to mediate microbe-microbe interactions (Lee et al. 2008, 
Mazmanian et al. 2008, Sassone-Corsi et al. 2016). Therefore, we considered if 
microcins also regulated microbe-host interactions by modulating epithelial derived 
CD1d immune responses in the host similar to other OxC compounds. To address this 
question, we focused our attention on Microcin B17 (MccB17, MCS=0.75), originally 
isolated from strains of Escherichia coli (E. coli) from the intestinal tract of newborns 
whose expression is linked to a plasmid (pMccB17) that carries the mcb operon, 
encoding the MccB17 toxin that acts as a DNA gyrase inhibitor (Table S1, Li et al. 1996). 
The mcb operon was cloned into a pUC19 vector and transformed into a competent E. 
coli BSL1 human commensal strain (MG1655) (Collin et al. 2013). Bacteria transformed 
with mcb17 or empty plasmid was grown in Luria Broth or M63 supplemented media to 
induce MccB17 synthesis (Collin et al. 2013) and bacterial lysates were incubated with 
IECs after which we measured CD1d-restricted IL-10 production. We observed that 
lysates from bacterial isolates transformed with mcb and grown under MccB17 
permissive conditions, attenuated CD1d-restricted IL-10 production in MODE-K:iNKT cell 
co-cultures, whereas lysates isolated from bacteria grown under non-permissive 
conditions or transformed with empty plasmid had no effect (Fig. 2A). To further examine 
whether suppression of CD1d-restricted responses was due to a MccB17 product, we 
purified full length mature MccB17 by High Performance Liquid Chromatography 
(HPLC). To our surprise, purified MccB17 exerted no effects on CD1d dependent IL-10 
production (Fig. 2B). Interestingly, although the full length MccB17 microcin consists of a 
3093 Da peptide, several smaller heterocyclic mcb17 derived heterocyclic species have 
been identified by MALDI-ToF mass spectrometry analysis some of which retain DNA 
gyrase inhibitory activity. We hypothesized that the immunomodulatory effects of the 
MccB17 positive lysate might be a result of proteolytic and/or degradative products 
rather than the mature full length MccB17 itself (Collin et al. 2013). B17 microcin is 
sensitive to cleavage by subtilisin but not trypsin (Asensio and Perez-Diaz 1976). 
Therefore, we digested purified full length B17 with each protease and measured CD1d-
restricted IL-10 responses in the IEC:iNKT cell co-culture assay to these proteolytic 
products (Fig. 2B). In this case, cleavage products from subtilisin but not trypsin were 
able to attenuate IL-10 production in IEC:iNKT co-cultures with -GC. Similarly, we 
observed decreased Mttp and increased Cyp1a1 transcripts in MODE-K cells incubated 
with MccB17 subtilisin proteolytic products but not full length B17 or MccB17 digested 
with trypsin (Fig. 2C).  
Taken together, these results suggested that the ability of MccB17 derived toxins 
to affect epithelial transcriptional and CD1d-restricted responses is limited by the size of 
the product. To clarify this size restriction, we synthesized and screened a library of 8 
MccB17 derivative products with molecular weights ranging from 183.17-857.82 Da 
whose anti-DNA gyrase activity has been previously described (Fig. 2D) (Collin et al. 
2013).  Consistent with our hypothesis, four fragments, containing permutations of 1 or 2 
oxazole/thiazole moieties, with MW<270 Da were able to modulate CD1d dependent IL-
10 production and regulate Mttp and Cyp1a1 whereas synthetic products >500Da were 
not (Fig. 2E, 2F and data not shown). Importantly, synthetic analogs capable of exerting 
immunomodulatory effects were within the relative size range of both oxazolone (217.22 
Da) and 2,4,5-trimethyl-2,5,-dihydro-1,3-oxazole (113.16 Da) but surprisingly even 
synthetic products that did not confer anti-DNA gyrase activity were able to generate 
epithelial responses (Fig. 2D, 2E, 2F). Furthermore, both oxazole and thiazole 
containing compounds generated similar effects consistent with their shared physico-
chemical properties (Fig. 2D, 2E, 2F). 
A synthetic B17 microcin derivative induces colonic inflammation in a CD1d-
dependent manner independent of anti-microbial activity. 
We next asked whether B17 microcin derivatives could induce intestinal inflammation in 
vivo. We therefore synthesized adequate quantities of a minimal B17 derivative (termed 
frag-oz, Fig. 2D) to perform in vivo experiments and challenged animals via intra-rectal 
administration. Like with oxazolone and TMO, we observed CD1d-dependent pathology 
as well as induction of both Th1 and Th2 cytokines from colon explants suggesting that 
this molecule induces inflammation in an iNKT dependent manner by comparing 
response in WT versus CD1d-deficient animals (CD1d KO) (Fig. 3A, 3B, 3C, S3A). We 
also observed decreased Mttp levels and induction of Cyp1a1 in IEC enriched colonic 
fractions suggesting that frag-oz exerts immunomodulatory effects via the epithelial 
compartment in vivo (Fig. 3D. 3E). Though in vitro studies showed that frag-oz confers 
no anti-gyrase activity (Collin et al. 2013), to formally distinguish whether the intestinal 
inflammation observed was due to its anti-microbial properties or its direct effects on the 
host, we challenged GF and SPF mice with frag-oz or vehicle. Consistent with the 
former, GF animals exhibited increased weight loss compared to animals raised under 
SPF conditions together with severe inflammation as defined by quantitative 
histopathology (Fig. 3C, 3F). These studies thus identify an oxazole containing microbial 
mimic that promotes CD1d-dependent intestinal inflammation independent of its 
classical anti-microbial activity. 
Activation of epithelial aryl hydrocarbon receptor pathways exacerbates response 
to dietary and microbial oxazole compounds by limiting IL-10 responses. 
The data presented support a model in which exposure to a broad class of oxazole (or 
thiazole) ring containing compounds can direct transcriptional changes in responsive 
tissue compartments, such as the intestinal epithelium, that influence CD1d-restricted 
antigen presentation pathways thereby augmenting iNKT (or non-invariant NKT) cell 
inflammatory responses leading to colitis. These data also suggest the presence of 
cellular sensor(s) that are responsible for recognizing and transducing oxazole 
dependent signals. Review of our previous microarray analyses identified two signature 
aryl hydrocarbon receptor (AhR) targets, cyp1a1 and Ido1, involved in P450 and 
tryptophan metabolism, respectively, as inducible gene targets in the colonic epithelium 
(Olszak et al. 2014). Here we demonstrate that oxazolone, vinclozolin, an industrial 
agent, and the dietary and microbial oxazole ligands, TMO and frag-oz, induced 
expression of these genes in vitro and in vivo. Interestingly, vinclozolin, an antifungal 
agent to which humans are exposed through agriculture and which affects CD1d-
restricted pathways as an OxC as shown here, has been described as an AhR activator 
(Wambaugh et al. 2014).  
We therefore transfected IECs with an AhR firefly luciferase reporter and 
observed that oxazolone, TMO and 5 additional dietary oxazoles, as well as 4 synthetic 
MccB17 derivatives induced robust AhR transcriptional activity compared to vehicle or a 
non-oxazole heterocyclic control, 1,2,4-trimethylcyclopentane (Fig. 4A). Consistent with 
this, siRNA mediated knockdown of AhR in MODE-K cells abrogated induction of cyp1a1 
and IDO1 and partially restored Mttp expression (Fig. S4A-C). Given that AhR regulates 
MTP expression we asked whether this pathway could modulate epithelial derived 
CD1d-restricted responses. Indeed, AhR deficiency caused by silencing AhR expression 
in epithelial cells reversed oxazolone, TMO or frag-oz mediated inhibition of CD1d-
restricted IL-10 production in IEC:iNKT cell co-cultures via reduction of cell surface 
CD1d lipid antigen loading (Fig. 4B, 4C). This was confirmed in hepatocytes obtained 
from Ahr-/- mice, which also exhibited resistance to the effects of oxazolone, TMO, frag-
oz or vinclozolin induced inhibition of IL-10 production in response to iNKT cells in the 
presence of -GC (Fig. S5). Interestingly, these effects were not attributed to general 
AhR function, but instead reflected a specific response to oxazole containing molecules 
as a human cognate AhR ligand, 2-(1H-Indol-3-carbonyl)-4-thiazolecarboxylic acid 
methyl ester (ITE), did not modulate Mttp expression or CD1d-restricted responses (Fig. 
4B, 4C). 
These studies reveal a novel role for epithelial derived AhR signals in promoting 
mucosal inflammation when exposed to OxC. Consistent with this hypothesis, deletion of 
Ahr specifically in IECs (generated by crossing Ahrfl/fl to Villin-Cre transgenic animals, 
AhrIEC) resulted in elevated IL-10 production in colonic explants after oxazolone or frag-
oz compared to wildtype controls (Fig. 4D), and conferred host protection to oxazolone 
(Fig. 4E, 4F) and frag-oz (Fig. 4G, 4H) after intra-rectal challenge as characterized by 
diminished weight loss and disease manifestations relative to that observed in Ahrfl/fl 
mice.  
Oxazoles induce the generation of tryptophan-derived metabolites that attenuate 
epithelial CD1d-restricted responses in an AhR dependent manner. 
Our studies show that although AhR regulates CD1d-restricted responses to oxazole 
containing compounds, this is not a property of all AhR ligands (such as ITE). This 
suggests that epithelial responses to OxC generate AhR agonists uniquely capable of 
attenuating IL-10 production through CD1d-restricted mechanisms. It was therefore of 
interest that we observed IDO1 upregulation in IECs exposed to oxazoles suggesting 
these compounds may increase IDO1 cellular activity (Fig. S1A). Indeed, incubation of 
recombinant human IDO1 with oxazolone, TMO or frag-oz enhanced the ability of IDO1 
to convert tryptophan to formyl-kynurenine compared to control (TMC) or vehicle 
indicating that oxazole compounds may function to enhance IDO1 enzymatic activity 
through direct mechanisms (Fig. 5A).  To test whether tryptophan metabolism is 
therefore involved in the AhR effects we observed, we cultured IECs in tryptophan-
deficient media and found that CD1d-restricted IL-10 production was no longer 
attenuated by stimulation with oxazolone, TMO or frag-oz when compared to TMC or 
vehicle controls (Fig. 5B). Supplementation with exogenous L-tryptophan (L-Trp) 
restored responses to oxazolone, TMO and frag-oz resulting in attenuation of CD1d-
restricted IL-10 production supporting a role for tryptophan-derived metabolites in this 
process (Fig. 5B). To specifically identify these tryptophan derived products, we cultured 
IECs with deuterated L-trp (D5-Trp) and performed high performance liquid 
chromatography mass spectrometry (LC-MS) on lysates stimulated with oxazolone, 
TMO, frag-oz or TMC control (Fig. 5C). We detected uptake of D5-Trp in TMC stimulated 
IECs that was further metabolized to kynurenic acid and 3-hydroxy kynurenic acid 
(referred to as xanthurenic acid) only upon stimulation with oxazolone or TMO and frag-
oz, respectively, within 6 hours of exposure to oxazoles (Fig. 5C). To further investigate 
whether tryptophan-derived metabolites attenuate CD1d-restricted responses, we 
cultured IECs in tryptophan-deficient media supplemented with L-Trp, kynurenic acid, 
xanthurenic acid, or an upstream tryptophan product, kynurenine, in the presence or 
absence of oxazolone. Supplementation with exogenous tryptophan or its downstream 
products of catabolism restored IEC responses to oxazolone as shown by reduced 
CD1d-restricted IL-10 production (Fig. 5D). In contrast, supplementation with DL-methyl 
tryptophan (DL-Mtrp) a tryptophan competitive inhibitor of IDO1 did not restore 
suppression of CD1d-restricted IL-10 production in IECs cultured in tryptophan-deficient 
conditions and stimulated with oxazolone (Fig. 5D). Finally, to ascertain whether these 
same metabolites identified in our LC-MS analyses, functioned through the AhR 
pathway, we performed siRNA-mediated knockdown of AhR in IECs cultured under 
tryptophan-deficient conditions in the presence of exogenously administered kynurenic 
acid and measured CD1d-restricted IL-10 production after stimulation with OxC 
compounds (Fig. 5E). Incubation of IECs with L-Trp or kynurenic acid alone or in 
conjunction with TMC stimulation had no effect on CD1d-restricted IL-10 production (Fig. 
5B, 5D). In contrast, IECs cultured under tryptophan-deficient conditions and stimulated 
with oxazolone, TMO or frag-oz when supplemented with kynurenic acid led to 
decreased IL-10 production that was reduced when AhR was silenced (Fig. 5E). Taken 
together these latter studies are consistent with a model in which exposure of IECs to 
oxazole containing compounds leads to the activation of IDO1 and generation of 
tryptophan-derived metabolites that induce the AhR pathway to downregulate CD1d-
restricted responses associated with the production of IL-10 (Fig. 6).  
Discussion 
In the studies described herein, we have used structural analyses of oxazolone, a 
compound previously shown to be capable of inducing inflammation of the colon 
(Boirevant et al. 1998, Heller et al. 2002), to identify a new and potentially broad class of 
environmental factors, derived from diet, microbes and other sources, we name oxazole-
containing (OxC) compounds. OxC compounds are capable of direct induction of 
intestinal inflammation through crosstalk of CD1d-restricted and aryl hydrocarbon 
receptor pathways in intestinal epithelial cells, and together, suggest that these 
environmental agents are capable of activating CD1d-restricted pathways by 
phenocopying host responses to microbial factors.  
Environmental and lifestyle factors have been identified as critical risk elements 
for development of disorders of chronic inflammation, such as IBD (Molodecky and 
Kaplan 2010). Consistent with this, chemical induced models of intestinal inflammation 
have been crucial experimental tools for investigating the pathophysiology and the 
testing of therapeutic strategies for IBD (Wirtz et al. 2007, Kaser et al. 2010). Here, we 
have isolated the colitogenic activity within oxazolone to a five-membered heterocyclic 
oxazole moiety. Based on these observations, we inquired whether oxazolone is 
representative of a broader class of environmental factors that may be involved in the 
pathogenesis of IBD and possess conserved or shared sub-structure. Oxazolone, first 
synthesized in 1883 by Erlenmeyer and Plochl (Plochl 1884, Erlenmeyer 1893), has 
been widely utilized as a synthetic building block for compounds with a range of 
pharmacological properties (Turchi 2008) and are also naturally abundant in diet as a 
component of many thermally processed foods, pesticides, and other environmental 
sources (Maga 1978).  In addition, microbes are another abundant source of oxazoles 
as part of a structurally functionally diverse class of ribosomally derived peptides dubbed 
thiazole/oxazole modified microcins (TOMMs) that are widely disseminated across the 
phylogenetic spectra of bacterial secretion systems, including potential pathobionts 
associated with IBD pathogenesis or skin inflammation (Mazmanian et al. 2008, Melby et 
al. 2011). Together, this supports the notion that dietary and microbial derived 
compounds with common sub-structure, like oxazoles, can modulate host response by 
converging on conserved host immune celular pathways (Fig. 6). 
We observed that exposure to select oxazole species modulate CD1d-restricted 
responses in epithelial cells in vitro which are characterized by down-regulation of Mttp 
and reduced IL-10 production after CD1d crosslinking with NKT cell associated 
receptors. This mechanism has been previously shown to reduce epithelial barrier 
activity in response to similar concentrations of oxazolone in the colon leading to 
exacerbated inflammatory responses (Olzsak et al. 2014). To what degree oxazole 
products accumulate within the intestinal tract and the physiological concentrations and 
circumstances required for triggering inflammatory responses are unknown. However, at 
least two of the structures we identified, 2,4,5-trimethyl-1,3-dihydro-oxazole (TMO) and 
vinclozolin have been detected in human urine through studies associated with defining 
the human exposome (Table S1, Wambaugh et al. 2014). Although not directly 
addressed in this study, it is interesting to consider whether accumulated exposure to 
oxazoles derived from multifactorial sources, including diet, microbes, industry and/or 
agriculture acts in an additive or combinatorial manner that includes other potential non-
oxazole agents in modulating host responses that are associated with disease 
pathogenesis. 
Our gene expression profiling of intestinal epithelial cells exposed to oxazole 
compounds have identified a several genes (Fig 1B, 2C, 2F, 3E, S1A, S4) involved in 
xenobiotic metabolism and tryptophan catabolism, including indoleamine 
2,3,dioxygenase 1 (IDO1), a marker highly expressed in patients suffering from IBD as 
well as in many animal models of colitis (Olszak et al. 2014, Ciorba et al. 2013, Wolf et 
al. 2004). Data presented here suggest that oxazole compounds directly enhance the 
ability of IDO1, the rate-limiting enzyme in tryptophan catabolism, to metabolize 
tryptophan (Fig. 5A). This supports a role for the aryl hydrocarbon receptor (AhR) as a 
potential cytosolic sensor or signal transducer of oxazole induced products in the 
intestinal epithelium (Lanis et al. 2017). Indeed, specific depletion of the AhR in the 
epithelium was shown to alleviate the oxazole-induced suppression of CD1d-restricted 
anti-inflammatory responses including production of IL-10 (Fig. 4B). Mass spectrometry 
analyses identified at least two products of tryptophan catabolism, kynurenic acid and 
xanthurenic acid, that are specifically generated in intestinal epithelial cells exposed to 
oxazolone or dietary and/or microbial oxazoles and their capacity to activate the AhR 
pathway in a manner that results in attenuation of CD1d-restricted IL-10 production. This 
observation is interesting given that levels of tryptophan and its byproducts in the serum 
have provided a robust marker for gastrointestinal pathology in clinical settings (Ciorba 
2013). 
In addition, we have shown that oxazoles also downregulate MTP which is 
normally responsible for the loading of phospholipid antigens onto CD1d (Dougan et al. 
2005, 2007). Consistent with our observations, altering MTP expression or activity has 
been previously shown to prevent transfer of phospholipids to CD1d or the ability of 
CD1d to acquire exogenous lipid antigens such as -GC (Dougan et al. 2005). Further, 
loss of MTP in IECs has been shown to disable the ability of iNKT cells to induce the 
barrier protective cytokine, IL-10, by this cell type as we have shown previously and 
demonstrated here (Olszak et al. 2014). Together, our data suggest that oxazoles alter 
presentation of lipid auto-antigens (Fig. S1B, S1C) and exogenous lipid antigens as 
shown with -GC (Fig. 1D,1E, 4C) to CD1d-restricted invariant and non-invariant NKT 
cells in a pathway that is dependent on AhR through the generation of tryptophan-
derived metabolites. As both oxazolone and frag-oz induce inflammation in animals 
under GF conditions (Olszak et al. 2012, Fig. 3D-E), NKT-mediated responses to host-
derived lipid antigens may be particularly important to oxazole-induced inflammation and 
further suggest oxazoles may thus modulate autoimmune responses to self-lipid 
antigens.  
Conversely, it is also interesting to consider whether microbes use oxazole 
products to target CD1d in order to establish their niche during primary colonization 
potentially resulting in mucosal inflammation and pathology. We have previously 
demonstrated an important physiological role for CD1d during initial colonization of 
commensal and pathogenic bacteria (Nieuwenhuis et al. 2009). Consequently, 
generation of products that modulate CD1d activity such as oxazoles, which are capable 
of specifically inhibiting intestinal epithelial cell function may affect the ability of microbes 
to colonize the intestine and potentially cause inflammation. While full length MccB17 
itself shared relatively low structural similarity with oxazolone, derivative products below 
270Da generated either by alkaline hydrolysis or proteolytic cleavage showed relatively 
high similarity with both oxazolone and TMO (Table S1). Importantly we have observed 
that both the natural products and their synthetic analogs display similar ability to 
attenuate CD1d-lipid antigen presentation and subsequent CD1d-restricted IL-10 
production as well as activate AhR responses specifically in IECs resulting in 
inflammation associated with decreased epithelial derived IL-10. That inflammation to 
MccB17 derivatives occurs in GF animals confirms that the effects of these compounds 
are directly impacting the host and not a result of their anti-microbial capacity. It is 
therefore intriguing to consider then that the accumulation of oxazole compounds 
derived from MccB17 producing and other TOMM producing bacterial strains during a 
period of microbial competition may have a bystander effect on host immune responses 
resulting in intestinal inflammation or other effects that benefit the organism at the 
expense of the host.  
In conclusion, our studies illustrate a strategic approach for identifying potential 
triggers of inflammation by interrogating and evaluating structural mimics of lead 
compounds with established host responses and pathology. In this manner, by 
leveraging the knowledge that oxazolone acts as a colitogenic agent via modulation of 
CD1d-restricted pathways we have identified oxazole containing compounds (OxC) as a 
new class of potential environmental agents with inflammation inducing potential that are 
contained within a wide range of environmental sources including diet and microbes. 
With respect to the latter, our studies further show that bacterial microcins, which are 
well known to play a role in microbe-microbe interactions, also possess important and 
previously unappreciated immune regulating properties via their effects on CD1d-
restricted pathways. Further, in both the case of environmental and microbial OxC we 
have found that they involve epithelial sensing by the AhR, which in turn adversely 
affects CD1d-restricted presentation of lipid antigens that are associated with barrier 
protective production of IL-10.  As a result, we also identified a novel pro-inflammatory 
role of AhR sensing that is associated with the intestinal epithelium and have brought 
forth the concept that environmental triggers of inflammation that are potentially 
associated with IBD may function in this manner by phenocopying the activity of 
microbial products with similar activity. 
Figure Legends 
Figure 1: A minimal oxazole structure modulates expression of specific gene 
targets and attenuates CD1d restricted in intestinal epithelial cells leading to 
colonic inflammation: A. Panel of oxazole containing and control heterocylic natural 
and synthetic compounds. B. Relative transcript abundance in MODE-K cells stimulated 
with indicated compounds, normalized to -actin. C.  Interleukin 10 production in MODE-
K cells conditioned with the indicated compounds, loaded with -Galactosyl Ceramide 
(-GC) followed by 24.7 iNKT hybridoma co-culture. D., E. Representative traces and 
quantification of surface CD1d loaded with -GC in MODE-K cells conditioned with 
indicated compounds. F. Weight change after intra-rectal administration of 1% TMO or 
EtOH (50% v/v) vehicle in wildtype (WT) or CD1d-deficient (KO) animals (n=16-20). 
*p<0.05 (Mann-Whitney U-test) G. Quantitative scoring for colitis after intra-rectal 
administration of 1% TMO or EtOH (50% v/v) vehicle in wildtype (WT) or CD1d-deficient 
(KO) animals (n=8). H. Quantification (ELISA) of Interleukin 13 and IFN- production 
from colon explants 2 days after intra-rectal administration of 1% TMO, TMC or EtOH 
(50% v/v) vehicle (n=3). ** p<0.01 (Student’s t-test). *p<0.05 **p<0.01’ ***p<0.001 
(Student’s t-test) 
Figure 2: Microbial derived oxazoles modulate CD1d restricted responses and 
regulate transcriptional targets in intestinal epithelial cells: Interleukin 10 response 
in MODE-K cells pre-conditioned with vehicle (DMSO) or indicated compounds: A. 
lysates from bacterial transformants (empty/pUC19, B17) grown in Luria Broth or M63 
supplement, B. purified MccB17 (B17) microcin and/or B17 microcin proteolytic digest 
(subtilisin, trypsin), and subsequently loaded with -GC followed by 24.7 iNKT 
hybridoma co-culture. C Relative transcript abundance of target genes, Mttp and Ido1, in 
MODE-K cells to -actin in MODE-K pre-conditioned as in B. D.  Panel of synthetic 
analogs of B17 microcin proteolysis products with indicated anti-microbial activity. E. 
Interleukin 10 response in MODE-K cells pre-conditioned with vehicle, oxazolone, or 
synthetic MccB17 microcin analogs, and subsequently loaded with -GC followed by 
24.7 iNKT hybridoma co-culture. F. Relative transcript abundance of target genes in 
MODE-K cells to -actin in MODE-K pre-conditioned as in E. *p<0.05; **p<0.01; 
***p<0.001 (Student’s t-test). 
Figure 3: NKT cells are required for colonic inflammation induced by Frag-oz: A. 
Quantitative scoring for colitis after intra-rectal administration of 1% TMO or EtOH (50% 
v/v) vehicle in wildtype (WT) or CD1d-deficient (KO) littermates (n=8). B. Quantification 
of Interleukin 13 and IFN- production in overnatant of colon explants 2 days after intra-
rectal administration of 1% TMO or EtOH (50% v/v) vehicle (n=6) C. Weight change after 
intra-rectal administration of 1% Frag-oz or EtOH (50% v/v) vehicle in Germ Free or 
specific pathogen free animals (n=8). **p<0.01; ***p<0.001 (Mann-Whitney U-test). 
Quantification of D. Mttp and E. Cyp1a1 transcripts (normalized to -actin) from mucosal 
scraping 2 days after intra-rectal administration of 1% Frag-oz, or EtOH (50% v/v) 
vehicle (n=4). **p<0.01; ***p<0.001 (Student’s t-test) F. Quantitative scoring for colitis 
after intra-rectal administration of 1% TMO or EtOH (50% v/v) vehicle in germ free or 
specific pathogen free animals (n=8-9).  **p<0.01; p<0.001 (Student’s t-test). 
Figure 4: Activation of Aryl Hydrocarbon Receptor by dietary and microbial 
derived oxazole compounds: A. Aryl Hydrocarbon Receptor promoter-reporter activity 
after MODE-K cells conditioned with indicated compounds. MODE-K cells transfected 
with scrambled (solid fill) or siRNA targeted against AhR (clear fill), conditioned with 
indicated compounds and then loaded with -GC followed by 24.7 iNKT hybridoma co-
culture B. Interleukin 10 production. C. Quantification of surface CD1d loaded with -
GC. D. Quantification of Interleukin 10 from overnatant of colon explants 3 days after 
intra-rectal administration of 1% oxazolone or 1% Frag-oz EtOH (50% v/v) vehicle in WT 
or animals with AhR-deficiency in epithelial compartment (AhrΔIEC). (n=4). Weight change 
after intra-rectal administration of E. 1% oxazolone or EtOH (50% v/v) vehicle or G. 1% 
Frag-oz or EtOH (50% v/v) vehicle in WT or animals with AhR-deficiency in epithelial 
compartment (AhrΔIEC). *** p<0.001 (Mann-Whitney U-test) F, H. Quantitative scoring for 
colitis after intra-rectal administration of oxazolone (F) or frag-oz (H) in EtOH (50% v/v) 
in WT or animals with AhR-deficiency in epithelial compartment (AhrΔIEC)  (N=5-10). 
*p<0.05; ** p<0.01; ***p<0.001 (Student’s t-test). 
Figure 5: Oxazoles induce the generation of tryptophan derived metabolites that 
attenuate epithelial CD1d-restricted responses in an AhR dependent manner: A. 
Recombinant IDO1 was incubated with L-tryptophan in the presence of oxazole 
(oxazolone, TMO, Frag-oz), control (TMC) compounds or vehicle and formyl-kynurenine 
production measured via calorimetric assay, B. MODE-K cells cultured with L-tryptophan 
deficient media or media supplemented with exogenous L-tryptophan and CD1d-
restricted Interleukin 10 responses measured in MODE-K cells pre-conditioned with 
vehicle or indicated compounds. C. LC-MS quantification of label retaining metabolites in 
MODE-K cells grown under tryptophan deficient conditions and supplemented with 
deuterated tryptophan and conditioned with the indicated compounds. D. CD1d-
restricted Interleukin 10 responses in MODE-K cells pre-conditioned with vehicle or 
oxazolone in tryptophan deficient media with supplementation with L-tryptophan, DL-
methyl tryptophan, kynurenine, kynurenic acid, or xanthurenic acid and then loaded with 
-GC followed by 24.7 iNKT hybridoma co-culture. E. CD1d-restricted Interleukin 10 
production by MODE-K cells transfected with scrambled (solid fill) or siRNA targeted 
against AhR (clear fill) in tryptophan deficient media. CD1d-restricted Interleukin 10 
responses were measured following pre-conditioning with vehicle, TMC, oxazolone, 
TMO or frag-oz with or without supplementation of L-tryptophan or kynurenic acid.  
***p<0.001 (Student’s t-test). 
Figure 6. Exposure to environmental oxazoles (from diet or microbes) influences 
CD1d-restricted responses in intestinal epithelial cells through production of 
tryptophan derivatives that activate the aryl hydrocarbon receptor pathway.  
Intestinal epithelial cells (IEC) promote mucosal barrier protection through microsomal 
triglyceride protein (MTP) mediated CD1d-restricted production of Interleukin 10 (IL-10, 
blue circles). Upon exposure to oxazole compounds (derived from diet, microbes or 
other environmental sources), these CD1d-restricted responses are attenuated through 
a mechanism involving the production of tryptophan derived metabolites (kynurenic acid, 
xanthurenic acid, orange squares), through the activity of IDO1, that trigger the aryl 
hydrocarbon receptor (AhR). Decreased, CD1d-restricted IL-10 production results in 
unrestrained inflammatory responses (IL-13/IFN, red dots) and resulting pathology.  ER 
(endoplasmic reticulum), IFN- (Interferon ). 
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STAR Methods 
 
Contact for Reagent and Resource Sharing 
Further information and requests of reagents can be directed to and fulfilled by the Lead 
Contact, Dr. Richard S. Blumberg (BLUMBERG@BWH.HARVARD.EDU). 
 
Experimental Model and Subject Details 
Animals 
Mice (C57Bl/6J) were housed in a specific pathogen-free (SPF) barrier facility at Harvard 
Medical School: Wildtype, Ahrfl/fl, Villin-Cre, mice were purchased from The Jackson 
Laboratory. Ahr-/- mice were purchased from Taconic USA and maintained as 
heterozygotes. Cd1d1-/-Cd1d2-/- have been described (Exley et al. 2003). Animal studies 
were conducted in a gender and age matched (8-10 week) manner using littermates for 
each experiment, except for wildtype versus Cd1d-/- comparisons. SPF and Germ-free 
animals were bred and maintained in vinyl isolators in the Harvard Digestive Disease 
Center Gnotobiotic and Microbiology Core. For colitis experiments, mice were 
transferred to Optimice cages (Animal Care Systems) for daily monitoring under sterile 
conditions. All procedures were approved by the Harvard Medical Area Standing 
Committee on Animals. 
Primary Cultures 
Bone marrow derived cells (BMDC) were purified from mouse femurs and cultured for 7 
days in RPMI (supplemented with 10% fetal bovine serum, 1% antibiotic-antimycotic, 
Gibco and 20 ng/mL granulocyte-macrophage colon-stimulating factor, Biosource). For 
primary hepatocyte isolation, mice were anesthetized with intraperitoneal injection of 
ketamine (87 mg/kg body weight) plus xylazine (13 mg/kg body weight), after which the 
inferior vena cava was exposed, cannulated and perfused for 5 min with liver perfusion 
media (Invitrogen), followed by a 10 min perfusion with liver digestion media (Invitrogen). 
The digested liver was minced in hepatocyte was media (Invitrogen) and cells were 
pelleted and resuspended in Williams E medium (10% FBS, 10-7M dexamethasone, 10 
g/ml insulin and 5 g/ml transferrin.  
Bacterial Stocks and Purification  
MccB17 was generated and purified as described (Collin et al. 2013, Li et al. 1996). 
Plasmid pUC19, wild-type or carrying the complete biosynthetic operon 
(mcbABCDEFG), was transformed into competent DH5 or MG1655 E. coli.  
Synthesis of Microcin B17 and Derivatives 
Overnight colonies were grown in LB media and used to inoculate M63 media (3 g/l 
KH2PO4, 7 g/l K2HPO4, 2 g/l (NH4)SO4, 1 mM MgSO4, 1 µg/ml thiamine, 0.2% glucose, 
0.1 mg/ml ampicillin) or LB Media (0.1mg/mL ampicillin) and incubated for 48 h. Cells 
were pelleted and lysed in a boiling solution of 1 mM EDTA and 100 mM acetic acid. 
Cellular debris was removed by centrifugation, protein was quantified by BCA Assay kit 
(ThermoFisher Scientific) according to manufacturer’s instructions and lysates were 
serially titrated (1g-10g/mL) incubated with MODE-K cells for co-culture assays as 
described. Digestion of full length MccB17 (a gift from A. Maxwell, Collin et al. 2013) by 
subtilisin (Sigma) (0.1 mM MccB17, 10% DMSO, 10 mM NaAcO, 5 mM Ca(AcO)2) or 
sequence grade trypsin (Promega) (0.5 mM 50 µg/mL trypsin, 1%DMSO in buffer 
(Promega) for 24 h to completion (Collin et al. 2013). Entire digested products (or 
equivalent buffer with enzyme) was then incubated with MODE-K cells for co-culture and 
qPCR analyses. 
Synthesis of Frag-oz 
Frag-oz, frag-tz, frag-oztz, and frag-tzoz originally were kindly provided by R. Payne, 
School of Chemistry University of Sydney or later synthesized by A.L. The compounds 
were synthesized according to established procedures for microcin B17-related oxazole 
and thiazole synthesis (Videnov et al. 1996). 
Refer to Figure S6A. Step 1. Synthesis of 2-(aminomethyl)oxazole-4-carboxamide (Fig 
S6A) 
Tert-butyl ((4-carbamoyloxazol-2-yl)methyl)carbamate 11 (0.895 g, 3.71 mmol)  was 
stirred in TFA/CH2Cl2 (1:1 v/v, 40 mL) at room temperature for 1 h. The solvent was 
removed under reduced pressure affording the title compound as a brown oil (0.367g, 
70%). 1H NMR (400 MHz, Methanol-d4) δ 8.42 (s, 1H), 4.28 (s, 2H). Step 2. 2-
(acetamidomethyl)oxazole-4-carboxamide (Frag-oz): To a solution of 2-
(aminomethyl)oxazole-4-carboxamide 2 (630mg, 4.46 mmol) in DMF (2.2 mL) at 0ºC 
TEA (0.7 mL, 4.9 mmol) was added followed by Acetyl Chloride (0.35 mL, 4.9 mmol). 
The solution was stirred for 5 h at 0ºC. The DMF was removed under reduced pressure 
and the crude product was purified by column chromatography on silica [DCM-Methanol, 
9:1 (v/v)] affording the title compound as a white solid (400mg, 49%). 1H NMR (400 MHz, 
Methanol-d4) δ 8.30 (s, 1H), 4.48 (s, 2H), 1.99 (s, 3H). 13C NMR (101 MHz, Methanol-d4) 
δ 172.12 , 163.71 , 161.52 , 142.01 , 135.76 , 35.87 , 20.92. 
Tert-butyl ((4-carbamoylthiazol-2-yl)methyl)carbamate (4) 
Aqueous ammonia (28% w/w, 3,1 mL, 40 mmol) was added to a solution of ethyl 2-
(((tert-butoxycarbonyl)amino)methyl)thiazole-4-carboxylate2 3 (381 mg, 1.33 mmol)  in 
methanol (1,3 mL). After 16 h at 45ºC, the reaction mixture was concentrated affording 
the title compound as a brown oil (315mg, 92%) which was used directñy in the next 
step. 1H NMR (400 MHz, Methanol-d4) δ 8.10 (s, 1H), 4.49 (s, 2H), 1.45 (s, 9H). 
2-(aminomethyl)thiazole-4-carboxamide (5) 
Tert-butyl ((4-carbamoylthiazol-2-yl)methyl)carbamate 4 (0.342 g, 1.331 mmol) was 
stirred in TFA/CH2Cl2 (1:1 v/v, 13 mL) at room temperature for 1.5 h. The solvent was 
removed under reduced pressure affording the title compound as a green oil (0.150, 
72%) which was used directly in the next step. 1H NMR (400 MHz, Methanol-d4) δ 8.25 
(s, 1H), 4.41 (s, 2H). 
Synthesis of Frag-tz 2-(acetamidomethyl)thiazole-4-carboxamide 
Refer to Fig. S6B. To a solution of 2-(aminomethyl)thiazole-4-carboxamide 5 (204mg, 
1.30 mmol) in DMF (6.5mL) at 0ºC, Triethylamine (TEA , 0.2 mL, 1.43 mmol) was added 
followed by Acetyl Chloride (0.1 mL, 1.43 mM). The solution was stirred for 5 h at 0ºC. 
The solvent was removed 
under reduced pressure and the crude product was purified by column chromatography 
on silica [CH2Cl2 /Methanol, 9:1 (v/v)] affording the title compound as a white solid 
(80mg, 31%). 1H NMR (400 MHz, Methanol-d4) δ 8.11 (s, 1H), 4.63 (s, 2H), 2.01 (s, 3H). 
13C NMR (101 MHz, Methanol-d4) δ 172.13 , 169.43 , 164.11 , 149.10 , 124.41 , 40.47 , 
21.01. 
Method Details 
Experimental colitis model 
For reciprocal sensitization studies (Fig. S3), mice were pre-sensitized by epicutaneous 
application of 3% w/v oxazolone (4-ethoxymethylene-2-phenyl-2-oxazolin-5-one, Sigma-
Aldrich) or 2,4,5-trimethyl-2,5-dihydro-1,3-oxazole (Sigma-Aldrich) in 100% ethanol (200 
L volume). Five days later, animals were re-challenged intra-rectally (through a 3.5F 
catheter) with 1% vehicle, oxazolone or 2,4,5-trimethyl-2,5-dihydro-1,3-oxazole in 50% 
ethanol (5 L/g of body weight) as indicated. For all other studies, vehicle, oxazolone, 
2,4,5-trimethyl-2,5-dihydro-1,3-oxazole, 1,2,4-trimethylcyclopentane (Sigma-Aldrich) 
were administered intra-rectally (through a 3.5F catheter) as a 1% solution in 50% 
ethanol (5 l/g of body weight). Body weight, rectal bleeding, and stool consistency were 
analyzed 1-2 times daily. Tissues obtained at the indicated time points were embedded 
in paraffin, stained with hematoxylin and eosin, and examined by a pathologist (Dr. Jon 
Glickman) in a blinded fashion for evidence of colitis according to five established 
criteria: mononuclear inflammation, crypt hyperplasia, epithelial injury, neutrophilic 
inflammation, and hypervascularization grading on 4 point scale (0=absent, 1=mild, 
2=moderate, 3=severe).   
Colon organ culture 
Standardized segments (1 cm × 1 cm) of the transverse colon were washed in cold PBS 
supplemented with penicillin and streptomycin (GIBCO) and cultured in 24-well flat-
bottom culture plates (Falcon) in RPMI 1640 media (GIBCO) for 24 h at 37°C. 
Supernatants were analyzed for cytokines IL-10, IL-13 and IL-1β by ELISA (all BD). 
Cells and Antigen presentation assays 
1 x 105 BMDCs, primary hepatocytes or 0.5 x 105 MODE-K cells (Vidal et al. 1993) were 
incubated in 96 well plates (Corning) maintained in RPMI (supplemented with 2% fetal 
bovine serum, 1% antibiotic-antimycotic, Gibco) were pulsed with the indicated 
compounds dissolved in dimethyl sulfoxide (DMSO) at a concentration of 10 M for 36-
48h. Cells were washed three times with sterile phosphate buffered saline (PBS, Gibco) 
after which cells were incubated with 100 ng ml-1 alpha-galactosyl ceramide/KRN7000 or 
beta-glucosyl ceramide (Avanti Polar Lipids) for 3h, washed three times with sterile PBS, 
before addition of 2 x 104 NKT hybridoma cells including 24.7, 24.8, and 14S6  overnight 
co-culture after which supernatant was collected and clarified by centrifugation. Mouse 
IL-10, IFN production was assessed by ELISA (OptEIA, BD Biosciences). For aryl 
hydrocarbon receptor siRNA mediated knockdown, MODE-K cells were transfected with 
AM100441, AM 100360, or Silencer negative control siRNAs (ThermoFisher Scientific) 
using Lipofectamine 2000 (Life Technologies) according to manufacturer’s instructions. 
AhR silencing was verified 48h after transfection by quantitative polymerase chain 
reaction. 
Identification of Tryptophan Derived Metabolites 
MODE-K cells were cultured in dialyzed FBS and RPMI (Gibco #26400044, RPMI 1640 
cGMP #100001229, all amino acids <1nM, ) and supplemented with essential amino 
acids (histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, and 
valine at 1M) and supplemented with deuterated tryptophan (1 M D5-Trp, Santa Cruz 
sc-391262, see Key Resources Table). Lysates were extracted from cell pellets in 80% 
Methanol and analyzed with reverse phase HPLC-MS (Agilent C18 column connected 
with Thermo Scientific LTQ-XL, see Key Resources Table). 
IDO1 enzymatic assay 
Recombinant His-tagged IDO1 was incubated with 10nM concentrations of TMC, 
oxazolone, TMO, or frag-oz and assay was performed according to the manufacturer’s 
instruction (BPS Bioscience, San Diego, CA, see Key Resources Table) 
CD1d and CD1d-lipid complex measurements by flow cytometry. 
MODE-K cells were pulsed with 10 M indicated compounds dissolved in DMSO for 36-
48h. Cells were washed three times with sterile PBS after which cells were incubated 
with 100 ng ml-1 alpha-galactosyl ceramide/KRN7000 or the non-agonistic compound, 
beta-glucosyl ceramide (data not shown), for 3 h, washed three times with sterile PBS. 
Cells were lifted in 10 mM EDTA/PBS and stained with the following antibodies: mouse 
L363 (eBiosciences, see Key Resources Table), mouse CD1d (BD Bioscience, see Key 
Resources Table). For intracellular staining, cells were fixed using the Intracellular 
Fixation and Permeabilization Buffer Set (eBioscience, see Key Resources Table) 
according to the manufacturer’s instructions. Flow cytometry was performed on 
MACSQuant Analyzer (Miltenyi Biotec) and analyzed using FlowJo software. 
Quantitative polymerase chain reaction assays 
RNA samples were prepared using an RNeasy Mini Kit and cDNAs were synthesized 
using the Omniscript RT Kit (Qiagen, see Key Resources Table). Real-time RT–PCR 
was performed using SYBR Green I Master Mix (Roche) and a CFX96 Real-Time 
System (Bio-Rad, see Key Resources Table). Values were normalized to β-actin (see 
Key Resources Table).  
Luciferase promoter-reporter assays 
 For aryl hydrocarbon receptor luciferase assays, MODE-K cells were cultured on 6-well 
plates (Corning). pGL4.43 Luc2pXRE (Promega) or empty pGL4.43 (Promega) and 100 
ng Renilla luciferase (Promega) was transfected into MODE-K cells using Lipofectamine 
2000. Twenty four hours later, MODE-K cells were conditioned with indicated 
compounds for 48 h. Cells were lysed and firefly luciferase (normalized to renilla 
luciferase) was measured using Dual Luciferase Reporter Assay System (Promega) 
In-silica similarity screening 
We used two-step in-silico screening process. First, broad similarity screening was 
performed to identify oxazole related natural compounds from various databases 
including Pubchem, Super Natural II a database of natural products (Bannerjee et al. 
2015), Dictionary of natural products Chemnet database, and The Human Metabolome 
Database (Wishart et al. 2013) (Table S1). Second, focused screen search was 
performed based on the results of first screening to identify natural compounds related to 
a 5-membered oxazole ring of oxazolone with emphasis to find minimal structural 
features of oxazolone for its inflammatory activity. This focused screen selection was 
based on identification of natural compounds with Tanimoto similarity of more than 0.5 
and/or Euclidean distance scores cutoff of 0.9 (Table S1). Natural compounds were 
queried in the standard SMILES format. Tanimoto similarities between compounds were 
computed with the Chemmine Similarity Workbench, which calculated maximum 
common substructure (MCS) similarities with the Tanimoto coefficient (Cao et al. 2008). 
Euclidean distance scores were calculated using Noncontiguous atom matching 
structural similarity function (NAMS) (Teixeira et al. 2013). The following formulas were 
used to calculate MCS similarity and TS score of natural compounds with Oxazolone 
and Oxazole ring substituted with a methyl group at the 2, 4 and 5 position. MCS 
similarity score: Atom number (AN) in MCS/AN in smaller molecule TS similarity score:  
AN in MCS/ (AN in smaller molecule + AN in larger molecule –AN in MCS). Based on the 
results of the screening process, 2,5-Dihydro-2,4,5-trimethyloxazole (TMO) with 
Tanimoto/Euclidean similarity score of 0.78/0.97 was selected as one of the natural 
compound for in vivo experiments. To further investigate the role of nitrogen and oxygen 
atoms of the oxazole ring and correlate them with colitogenic activity, 
Trimethylcyclopentane (TMC) and 2-Methyl-1-pyrroline (1MP) were selected as 
additional controls. In addition, Vinclozolin was selected based on Euclidean distance 
score of 0.94 and widespread fungicide usage.             
 
Supplementary Figures 
Table S1 (Refers to Figure 1): Oxazole-like structures identified by in silica screen 
against three chemical databases of naturally occurring compounds (Human 
Metabolome Database, Super Natural II database, Dictionary of Natural Compounds 
(Banerjee et al. 2015, Wishart et al 2007) using 3 parameters: Maximum Common 
Structure (MCS Similarity), Tanimoto similarity (Tc Similarity, Euclidean Distance Score). 
Figure S1 (Refers to Figure 1). A minimal oxazole structure modulates intestinal 
epithelial transcriptional and antigen presentation capacity to invariant and non-
variant NKT cells. A. Relative transcript abundance in MODE-K cells conditioned with 
the indicated compounds, normalized to -actin. **p<0.01 (Student’s t-test). B. CD1d-
restricted Interleukin 10 production in the absence of exogenous lipid supplementation in 
MODE-K cells conditioned with the indicated compounds followed by co-culture with B. 
invariant NKT (24.8) or C. non-invariant NKT (14S.6) hybridomas. ***p<0.001 (Student’s 
t-test). D. Interferon  production in bone marrow derived dendritic cells conditioned with 
the indicated compounds followed by loading with -galactosyl ceramide and co-cultured 
with 24.7 iNKT hybridoma. 
Figure S2 (Refers to Figure 1): A minimal oxazole structure does not alter CD1d 
protein expression or cellular distribution: Quantification of surface and intra-cellular 
CD1d protein expression in MODE-K cells conditioned with the indicated compounds for 
48hr, as measured by A. flow cytometry and, B. relative proportions of intracellular and 
cell surface CD1d protein abundance. 
Figure S3 (refers to Figure 3): Intestinal inflammation, epithelial response and 
pathology to oxazole containing compounds does not require apriori host 
sensitization. A. Representative sections of wildtype animals administered 1% of the 
indicated compounds (50% EtOH v/v) by intra-rectal challenge and analyzed by H&E 
stain after 3 days. 10X magnification, scale bar (40 M). Quantification of B. Mttp and C. 
Cyp1a1 transcripts (normalized to -actin) from mucosal scrapings 2 days after intra-
rectal challenge with 1% TMO, 1% TMC or EtOH (50%v/v) vehicle (n=3). *p<0.05, 
***p<0.001 (Student’s t-test). D. Animals were sensitized by topical application of the 
indicated compounds followed by intra-rectal administration of 1% TMO, 1% oxazolone, 
or EtOH (50% v/v) vehicle in wildtype C57Bl/6 animals. Quantitative colitis scoring was 
assessed on colons harvested 3 days after intra-rectal challenge. ***p<0.001 (Student’s 
t-test). 
Figure S4 (refers to Figure 4): Aryl hydrocarbon receptor mediates expression of a 
subset of gene targets in response to oxazole containing compounds: MODE-K 
cells transfected with control or AhR specific siRNA, conditioned with the indicated 
compounds and relative transcript abundance was measured normalized to -actin. A. 
cyp1a1, B. Ido1, C. Mttp  ***p<0.001 (Student’s t-test). 
Figure S5 (refers to Figure 4): Aryl hydrocarbon receptor attenuates CD1d-
restricted responses in primary hepatocytes: Interleukin 10 production from primary 
hepatocytes derived from WT or AhR-deficient (KO) animals were conditioned with the 
indicated compounds, loaded with -galactosyl ceramide followed by co-culture with 
24.7 iNKT hybridoma. *** p<0.001 (Student’s t-test). 
Figure S6 (Refers to STAR Methods): Synthesis of Frag-oz and Frag-tz.  
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Key Resources Table   
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies   
anti-mouse CD1d (1B1) FITC 
BD 
Biosciences Cat# 553845 
anti-mouse a-GalCer:CD1d 
complex PE Biolegend Cat# 140505 
anti-mouse aryl hydrocarbon 
receptor PE 
BD 
Biosciences Cat# 5657711 
Commercial Assays and 
Reagents   
Mouse IL-13 DuoSet ELISA 
R&D 
Systems Cat# DY413 
Mouse IFN-γ ELISA MAX Biolegend Cat# 430801 
Mouse IL-10 ELISA Ready-Set-Go eBioscience Cat# 501125188 
IDO1 Inhibitor Screening Assay Kit 
BPS 
Biosciences Cat# 72021 
Luciferase Assay System Promega Cat# E4550 
Lipofectamine 2000 
Thermo 
Fisher 
Scientific Cat# 11668019 
Intracellular Fixation and 
Permeablization Buffer Set eBioscience Cat# 88882400 
Omniscript RT Kit Qiagen Cat# 205111 
SYBR Green I  Roche Cat# 3003230001 
   
Oligonucleotides   
5′-GATGCTCCCCGGGCTGTATT-3′ 
Mouse Bactin 
qPCR 
Forward 
Primer R.S.B. Laboratory 
5′-GGGGTA CTTCAGGGTCAGGA-3′ 
Mouse Bactin 
qPCR 
Reverse 
Primer R.S.B. Laboratory 
5′-GAGAGCTGCAGGGCCCTTTGC-3′  
Mouse 
Interleukin 10 
qPCR 
Forward 
Primer R.S.B. Laboratory 
5′-
CTCCCTGGTTTCTCTTCCCAAGACC-
3′ 
Mouse 
Interleukin 10 
qPCR 
Reverse 
Primer R.S.B. Laboratory 
5′-GCAGCCAGTACGCTCTTTTC-3′  
Mouse CD1d 
qPCR R.S.B. Laboratory 
Key Resource Table
Forward 
Primer 
5′-ACAGCTTGTTTCTGGC AGGT-3′ 
Mouse CD1d 
qPCR 
Reverse 
Primer R.S.B. Laboratory 
′-
GGACTTTTTGGATTTCAAAAGTGAC-
3′ 
Mouse Mttp 
qPCR 
Forward 
Primer R.S.B. Laboratory 
5′-GGAGAAACGGTCATAATTGTG-3′ 
Mouse Mttp 
qPCR 
Reverse 
Primer R.S.B. Laboratory 
5'-TGGCACTCAGTAAAATATCTCCT-
3' 
Mouse IDO1 
qPCR 
Forward 
Primer R.S.B. Laboratory 
5'CAGGCAGATTTCTAGCCACA-3' 
Mouse IDO1 
qPCR 
Reverse 
Primer R.S.B. Laboratory 
5'-GGCCACTTTGACCCTTACAA-3' 
Mouse 
Cyp1a1 qPCR 
Forward 
Primer R.S.B. Laboratory 
5'-CAGGTAACGGAGGACAGGAA-3' 
Mouse 
Cyp1a1 qPCR 
Reverse 
Primer R.S.B. Laboratory 
mouse AhR siRNA 
Thermo Fisher 
Scientific Cat# 100360 
control siRNA 
Thermo Fisher 
Scientific Cat# AM4611 
   
Cell Lines   
MODE-K small intestinal epithelial 
cell line 
Vidal et al. 
1993 R.S.B. Laboratory 
24.7 invariant Natural Killer T cell 
hybridoma 
Behar et al. 
1999 R.S.B. Laboratory 
24.8 invariant Natural Killer T cell 
hybridoma 
Behar et al. 
1999 R.S.B. Laboratory 
14S.6 non-invariant Naturall Killer T 
cell hybridoma 
Behar et al. 
1999 R.S.B. Laboratory 
   
Experimental 
Models:Organisms/Strains   
C57Bl/6J Specific Pathogen Free 
The Jackson 
Laboratory Cat# 000664 
CD1d -/-  
Smiley et al. 
1997 R.S.B. Laboratory 
Ahr tm3.1Bra/J 
The Jackson 
Laboratory Cat# 006203 
Villin-Cre 
el Marjou et 
al. 2004 R.S.B. Laboratory 
C57Bl/6 Germ Free 
Harvard 
Digestive 
Disease 
Center R.S.B. Laboratory 
AhR -/- Taconic Cat# 9166 
C57Bl/6  Taconic Cat# B6 
   
Recombinant DNA   
pGL4.43 Luc2pXRE  Promega Cat# E4121 
pGL4.75 Promega Cat# E6931 
Renilla luciferase Promega Cat# E2261 
   
Software and Algorithms   
Graphpad Prism 7.0 
GraphPad 
Sofware, Inc. https://www.graphpad.com/ 
FloJo 
FloJo, LLC 
and Illumina, 
Inc https://www.flowjo.com/ 
   
Instruments   
Nikon Eclipse Ti Microscope Nikon  
BD FACS Aria II 
BD 
Biosciences  
MACSQuant Analyzer  
Miltenyi 
Biotec  
LTQ-XL Linear Ion Trap Mass 
Spectrometer 
Thermo 
Fisher 
Scientific  
CFX96 Real-Time System Bio-Rad  
   
Compounds   
4-Ethoxymethylene-2-phenyl-2-
oxazolin-5-one Sigma Cat# 862207 
2,4,5-trimethyl-2,5-dihydro-1,3-
oxazole Sigma Cat# CDS001470 
2-methyl-1-pyrroline Sigma 381055 
Frag-oz 
Collin et al. 
2013 A.L Laboratory 
Frag-tz Collin et al. A.L. Laboratory 
2013 
frag-oztz 
Collin et al. 
2013 A.M. Laboratory 
frag-tzoz 
Collin et al. 
2013 A.M. Laboratory 
Microcin B17 
Collin et al. 
2013 A.M. Laboratory 
Vinclozolin Sigma Cat# 45705 
L-Tryptophan Sigma Cat# T0254 
DL-methyl tryptophan Sigma Cat# 860646 
L-trytophan-D5 Sigma Cat# sc-391262A 
ITE Tocris Cat# 1803 
Subtilisin Sigma Cat# P5380 
Kynurenic-3,5,6,7,8-d5 
CDN 
Isotopes Cat# D-4391 
L-Kynurenine Sigma Cat# K8625 
Kynurenic Acid Sigma Cat# K3375 
4,8-dihydroxyquinoline-2-carboxylic 
acid Sigma Cat# D120804 
KRN7000 
Avanti Polar 
Lipids, Inc Cat# 867000 
beta-glucosyl ceramide 
Avanti Polar 
Lipids, Inc Cat# 860547P 
1,2,4-trimethyl cyclopentane Sigma Cat# R289728 
   
Cell Culture Reagents   
Dialyzed FBS Gibco 
custom for R.S.B. 
Laboratory 
Dialyzed RPMI Gibco 
custom for R.S.B. 
Laboratory 
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